Pregnancy outcome of FVQ/QThbdPro/+ females mated to ThbdPro/Pro males
| Experimental manipulation . | Stage of analysis (dpc) . | Parental genotype . | Genotype of live embryos (number/%) . | Number (%) of aborted embryos . | Number of embryos/ pregnancies analyzed . | ||
|---|---|---|---|---|---|---|---|
| Female . | Male . | FVQ/+ThbdPro/+ . | FVQ/+ThbdPro/Pro . | ||||
| None | 12.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 22 (100%) | 0* | 51 (69.9%) | 73 (8) |
| LMWH | 16.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 21 (60%) | 14 (40%) | 18 (34%) | 53 (7) |
| Lepirudin | 16.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 21 (100%) | 0* | 27 (56.2%) | 48 (6) |
| Fondaparinux | 16.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 25 (96.2%) | 1* (3.8%) | 20 (43.5%) | 46 (6) |
| Xa inhibitor C921-78 | 15.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 36 (90%) | 4* (10%) | 35 (46.7%) | 75 (8) |
| Mother Par3−/− | 15.5 | Par3−/− | ThbdPro/Pro | 54 (65.9%) | 28* (34.1%) | 41 (33.3%) | 123 (13) |
| FVQ/QThbdPro/+ | |||||||
| Mother β3LA/LA | 15.5 | β3LA/LA | ThbdPro/Pro | 27 (93.1%) | 2* (6.9%) | 72 (71.3%) | 101 (12) |
| FVQ/QThbdPro/+ | |||||||
| Mother β3LA/LA | 12.5 | β3LA/LA | ThbdPro/Pro | 9 (100%) | 0* | 9 (50%) | 18 (2) |
| FVQ/QThbdPro/+ | |||||||
| Experimental manipulation . | Stage of analysis (dpc) . | Parental genotype . | Genotype of live embryos (number/%) . | Number (%) of aborted embryos . | Number of embryos/ pregnancies analyzed . | ||
|---|---|---|---|---|---|---|---|
| Female . | Male . | FVQ/+ThbdPro/+ . | FVQ/+ThbdPro/Pro . | ||||
| None | 12.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 22 (100%) | 0* | 51 (69.9%) | 73 (8) |
| LMWH | 16.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 21 (60%) | 14 (40%) | 18 (34%) | 53 (7) |
| Lepirudin | 16.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 21 (100%) | 0* | 27 (56.2%) | 48 (6) |
| Fondaparinux | 16.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 25 (96.2%) | 1* (3.8%) | 20 (43.5%) | 46 (6) |
| Xa inhibitor C921-78 | 15.5 | FVQ/QThbdPro/+ | ThbdPro/Pro | 36 (90%) | 4* (10%) | 35 (46.7%) | 75 (8) |
| Mother Par3−/− | 15.5 | Par3−/− | ThbdPro/Pro | 54 (65.9%) | 28* (34.1%) | 41 (33.3%) | 123 (13) |
| FVQ/QThbdPro/+ | |||||||
| Mother β3LA/LA | 15.5 | β3LA/LA | ThbdPro/Pro | 27 (93.1%) | 2* (6.9%) | 72 (71.3%) | 101 (12) |
| FVQ/QThbdPro/+ | |||||||
| Mother β3LA/LA | 12.5 | β3LA/LA | ThbdPro/Pro | 9 (100%) | 0* | 9 (50%) | 18 (2) |
| FVQ/QThbdPro/+ | |||||||
ThbdPro/Pro embryos die in midgestation in pregnancies carried by FVQ/QThbdPro/+ females (row 1), but survive if the mother is treated with LMWH (row 2) or is deficient in Par3 (row 6). Anticoagulation with lepirudin (row 3), fondaparinux (row 4), or C921-78 (row 5) or genetic attenuation of maternal platelet aggregation (rows 7 and 8) does not result in comparable rescue. Equal proportions (50% each) of the ThbdPro/+ and ThbdPro/Pro embryos are expected from these crosses.
There is a significant difference from expected proportions (P value < .05) based on the χ2 GOF test.